Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2025)

Historic Gross Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 85.22%.

  • Xeris Biopharma Holdings' Gross Margin rose 102600.0% to 85.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.56%, marking a year-over-year increase of 32000.0%. This contributed to the annual value of 81.86% for FY2024, which is 6600.0% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Gross Margin is 85.22%, which was up 102600.0% from 83.37% recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Gross Margin peaked at 85.48% during Q1 2025, and registered a low of 62.01% during Q2 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Gross Margin value was 82.3% (recorded in 2022), while the average stood at 79.8%.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Gross Margin surged by 236300bps in 2021 and then plummeted by -80800bps in 2024.
  • Xeris Biopharma Holdings' Gross Margin (Quarter) stood at 77.19% in 2021, then grew by 5bps to 81.02% in 2022, then grew by 2bps to 82.95% in 2023, then rose by 2bps to 84.23% in 2024, then rose by 1bps to 85.22% in 2025.
  • Its Gross Margin stands at 85.22% for Q3 2025, versus 83.37% for Q2 2025 and 85.48% for Q1 2025.